NRX Pharma Advances Ketamine FDA Review and Expands Mental Health Pipeline

May 19, 2026

NRX Pharmaceuticals (NASDAQ: NRXP) reported first-quarter 2026 financial results while highlighting continued progress across its ketamine and mental health treatment pipeline. The company expects an FDA decision in the third quarter on its preservative-free ketamine ANDA, following favorable preliminary feedback from the FDA Office of Generic Drugs.

NRX also advanced development of NRX-101, including FDA acceptance of an IND for a federally supported study combining the therapy with robotic transcranial magnetic stimulation (TMS). Meanwhile, the company continues expanding its Hope Therapeutics subsidiary focused on integrated mental health treatment solutions.

#NRXPharma
#NRXP
#Ketamine
#MentalHealth
#Depression
#PTSD
#Biotech
#ClinicalTrials
#FDA
#HealthcareInnovation
#Neuroscience
#DrugDevelopment
#TMS
#JaneKing
#NewsOut